BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 21, 2008
 |  BioCentury  |  Strategy

Primary care cornerstone

Although a number of companies are rumored to have active programs targeting orexin, the only two disclosed clinical-stage programs are being run by partners GlaxoSmithKline plc and Human Genome Sciences Inc. on one hand, and by Actelion Ltd. on the other. With the former on hold due to a preclinical safety signal, GSK last week teamed up to develop Actelion’s almorexant, which is in Phase III trials to treat primary insomnia.

Orexins are neuropeptides produced by a very small number of dedicated neurons located in the hypothalamus that have been shown to play an important role in maintaining wakefulness and regulating the sleep-wake cycle. According to Actelion, almorexant (ACT-078573) is an oral orexin receptor antagonist that penetrates the blood-brain barrier and is capable of inducing a transient and reversible blockade of the orexin 1 receptor (OX1R) and orexin 2 receptor (OX2R).

In animal models, almorexant resulted in an increase in rapid eye movement (REM) sleep. In contrast, the...

Read the full 822 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >